Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=1002
Platelets are small blood particles that clump together to form clots. Sometimes, these clots may lead to myocardial infarction or a sudden blockage in the coronary artery. Antiplatelets are a class of drugs that inhibit blood clot formation. Many heart attack and stroke patients are treated with two types of antiplatelet drugs to prevent blood clotting. This is known as dual antiplatelet therapy. Dual antiplatelet therapy is a combination therapy which utilizes two antiplatelet drugs. One of the drugs in dual antiplatelet therapy is aspirin. Patients who have coronary artery disease, heart attack, coronary artery bypass surgery or stents are treated with aspirin for the rest of their life. The second drug in dual antiplatelet therapy is a P2Y12 inhibitor – either clopidogrel, pasugrel, or ticagrelor. Dual antiplatelet therapy leads to greater platelet inhibition than what is achieved by aspirin alone, thus, decreasing the likelihood of future blood clot formations in the coronary arteries and heart attacks.
Dual Antiplatelet Therapy Market: Drivers and Restraints
The growing prevalence and recurrence of cardiac diseases is expected to be the major factor driving the growth of the dual antiplatelet therapy market over the forecast period. According to World Health Organization, cardiac disease is the number one cause of death globally. An estimated 17.2 million people die of cardiac diseases, representing 31% of global deaths, annually. Off the 17.2 million people, approximately 7.4 million people died due to coronary heart disease, whereas nearly 6.7 million died due to stroke. Changes in lifestyle and eating habits are attributed to the growing prevalence of cardiac diseases. Research & Development of antiplatelet therapies is another factor contributing to the growth of the global dual antiplatelet therapy market. However, costs associated and lack of awareness about dual antiplatelet therapy market are some of the factors restraining the growth of dual antiplatelet therapy market.
Dual Antiplatelet Therapy Market: Segmentation
Tentatively, the global dual antiplatelet therapy market can be segmented on the basis of product type, indication, distribution channel, and geography.
Based on product type, the global dual antiplatelet therapy market is segmented as:
Dual Antiplatelet Therapy Market: Overview
The global market for dual antiplatelet therapy is expected to witness moderate growth over the forecast period. There is a high competition among local and regional players as majority of the antibiotics are introduced in the generic market. Among the two treatment types, the antibiotic treatment segment is expected to lead in the global dual antiplatelet therapy market over the forecast period. Retail pharmacy distribution channel is expected to contribute high share in the global dual antiplatelet therapy market as it is the most accessible channel and majority of the patients are recommended for outpatient treatment.
To know more about the Dual Antiplatelet Therapy Market Trends, Visit the link- https://www.factmr.com/report/1002/dual-antiplatelet-therapy-market
Dual Antiplatelet Therapy Market: Regional Outlook
Geographically, the global dual antiplatelet therapy market is segmented into viz. North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to be a dominant market in the global dual antiplatelet therapy market owing to high prevalence of the disease. The dual antiplatelet therapy market in Asia Pacific excluding Japan is expected to grow at a significant CAGR due to increasing prevalence of cardiac diseases. Europe is expected to have the second largest share in the global dual antiplatelet therapy market throughout the forecast period.
Dual Antiplatelet Therapy Market: Key Players
The global market for dual antiplatelet therapy is highly fragmented. Examples of some of the key players operating in the global dual antiplatelet therapy market are Bayer AG, Novacap, Shiono Chemical Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Eli Lilly & Co. Ltd. and others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
- Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
- Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
- Middle East and Africa (GCC, S. Africa, Rest Of MEA)
Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=1002
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Rockville, MD 20852
Read Industry News at – https://myconnectherald.com/